India's cheap generic semaglutide sales lag far behind forecasts

The flood of cheaper copycat semaglutide that reached Indian pharmacies after the country's patents on the drug expired in March has not taken over the market as fast as analysts predicted ^[1]. Through July, Indian sales of generic GLP-1 drugs totaled about 20% of the $261 million that brokerage Nomura Holdings had forecast for all of 2026, according to data from researcher Pharmarack Technologies ^[1].

Bloomberg cited distribution, pen supply and physician habits as factors slowing adoption ^[1]. By July, roughly three dozen generic GLP-1 products had reached pharmacies in India ^[1].

Price is not the obstacle. In March, at least five Indian manufacturers launched generic semaglutide at up to 80% below Novo Nordisk's original Indian prices ^[2]. Sun Pharmaceutical priced a weekly injection as low as 750 rupees, about $8, or roughly 3,400 rupees a month, against Novo's retail price of 8,800 to 10,000 rupees depending on dose ^[2]. Dr. Reddy's Laboratories launched a diabetes version at about 4,200 rupees a month ^[2]. Smaller domestic manufacturers discounted more deeply: Natco Pharma's vial formulation was priced at 1,250 rupees a month, and Alkem Laboratories' prefilled injections started at 1,800 rupees a month ^[2]. Bloomberg reported some prices as low as $14 a month ^[1].

Novo Nordisk has defended its position rather than ceding it. In December 2025, before the patent expired, the company cut the price of Wegovy in India by 37%, Reuters reported ^[2]. It also launched Wegovy under the name Poviztra through a partnership with Emcure Pharma and markets Ozempic as Extensior with Abbott India, arrangements that analysts said bring ties to pharmacies and physicians ^[2]. "The brand is essentially the moat," pharma consultant Salil Kallianpur told CNBC ^[2].

Demand itself was never in question. India has about 100 million people living with diabetes and nearly a quarter of its population classified as obese ^[2]. GLP-1 sales in the country rose 178% year over year to 14.46 billion rupees in the 12 months ending in February, according to Pharmarack ^[2]. Yet Rajiv Kovil, a Mumbai diabetes specialist, told CNBC that nearly 50% of his patients could benefit from GLP-1 drugs and only 5% were using them ^[2].

Whether Novo keeps its lead is not settled. Sydbank analyst Soren Lontoft Hansen said generics will affect Novo's Indian sales, but it is not yet clear whether the company will lose its leading position ^[2].

Why it matters for patients

US patients are not directly affected by the Indian price cuts. Semaglutide remains protected from generic competition in the United States until 2032, and the US is the drug's largest market by far ^[2]. No generic semaglutide is authorized for US sale on that timeline, so the Indian discounts do not change what Americans pay.

The Indian experience is a test of whether cheap copies actually reach patients. Prices there fell by as much as 80% ^[2] and sales still lagged forecasts ^[1]. Access depends on supply chains, cold-chain storage, distribution to smaller cities and whether doctors switch patients away from brands they know — factors that price alone does not fix ^[1][2]. Semaglutide is a peptide-based medicine that needs specialized manufacturing and cold-chain storage, which makes it harder to produce than most drugs India makes ^[2].

There is also the question of whether copies stay where patents have expired. Ben van der Schaaf, a partner at Arthur D. Little, told CNBC that some industry watchers worry large-scale GLP-1 manufacturing in India will not all remain in India ^[2]. Whether any generic semaglutide has been diverted into patent-protected markets has not been reported.

What happens next

Novo Nordisk has given no official indication of a fresh round of price cuts in India ^[2]. Dr. Reddy's said it plans to expand semaglutide sales to Canada, Turkey and Brazil this year and is targeting 12 million pens in its first year across all markets ^[2]. Semaglutide patents are also expiring this year in Canada, Brazil and China ^[2]. Novo warned in February that its sales could decline 5% to 13% in 2026 ^[2].